



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 13:04  
**Last Report Issued** 10/16/2018 12:08

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 3286SP  
**Patient ID** 3286SP  
**Chain** 18001707  
**Age** Not Given **DOB** Not Given  
**Gender** Not Given  
**Workorder** 18001707  
**Received** 10/16/2018 08:54

**Sample ID** 18001707-001  
**Matrix** Serum or Plasma  
**Patient Name** 3286SP  
**Patient ID** 3286SP  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

**3286SP Oxaprozin, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

Oxaprozin	None Detected	mcg/mL	3.0	
Synonym(s): Daypro®				

Single oral doses of 1200 mg oxaprozin resulted in peak plasma concentrations of 70 mcg/mL at 5 hours in men and 81 mcg/mL at 10 hours in women.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.